First Wave Biopharma Received Topline Results From Phase 2 SPAN Trial Of Formulated Adrulipase For Exocrine Pancreatic Insufficiency In Cystic Fibrosis Patients; Preliminary Data Indicate That It Is Unlikely The Primary Efficacy Endpoint Was Achieved
Portfolio Pulse from Benzinga Newsdesk
First Wave Biopharma has received topline results from its Phase 2 SPAN trial of formulated Adrulipase for Exocrine Pancreatic Insufficiency in Cystic Fibrosis patients. The preliminary data suggests that it is unlikely the primary efficacy endpoint was achieved.
July 13, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
First Wave Biopharma's Phase 2 trial results indicate that the primary efficacy endpoint was likely not achieved, which could negatively impact the company's stock price.
Clinical trial results are a significant factor in a biopharmaceutical company's valuation. The preliminary data indicating that the primary efficacy endpoint was not achieved could be seen as a failure, potentially leading to a decrease in First Wave Biopharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100